Compare USIO & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USIO | BYSI |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.2M | 58.4M |
| IPO Year | 1999 | 2016 |
| Metric | USIO | BYSI |
|---|---|---|
| Price | $2.21 | $1.69 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 119.9K | 13.7K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,200,535.00 | N/A |
| Revenue This Year | $12.15 | N/A |
| Revenue Next Year | $8.57 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 12.69 | N/A |
| 52 Week Low | $1.03 | $1.18 |
| 52 Week High | $2.23 | $2.50 |
| Indicator | USIO | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 75.39 | 52.69 |
| Support Level | $1.36 | $1.56 |
| Resistance Level | N/A | $1.83 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 88.71 | 50.00 |
Usio Inc is a cloud-based Fintech payment processor. The company serves multiple industry verticals with technology that facilitates payment acceptance and funds disbursement in a single, full-stack ecosystem. It provides payment acceptance through multiple payment methods, including payment facilitation, prepaid card, and electronic billing products and services to businesses, merchants, and consumers. The company's reportable operating segments are Output Solutions and Merchant Services, and these segments.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.